Saturday 17 October 2026
Export SNTI’s income statement to Excel — free account
Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
0.22
0.04
−15.38%
Follow SNTI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(394.62%) | (393.35%) | (255.03%) | (466.46%) | |
| (86.19%) | (82.43%) | (85.19%) | (97.52%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(191.69%) | (276.92%) | (408.39%) | (571.34%) | |
Average Days of Receivables |
0.00 | 0.00 | 108.35 | 1,376.28 | |
Free Cash Flow per Share |
(1.91) | (1.94) | (1.19) | (1.22) | |
Free Cash Flow |
(50.21) | (43.64) | (36.94) | (37.94) | |
Capital Expenditures |
(0.13) | (0.19) | (0.07) | 0.11 | |
| Other line items | |||||
Cash ROIC |
(246.55%) | (198.28%) | (321.26%) | (1,238.96%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.73 | 0.30 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,303.30% | 2,394.80% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 980.99% | 1,930.43% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 225.73% | 408.18% | |
Operating CF/Net income |
1.05 | 0.71 | 0.72 | 0.77 | |
Depreciation/Fixed assets |
0.20 | 0.28 | 0.28 | 0.28 | |
Capex/Depreciation |
(0.04) | (0.05) | (0.02) | 0.04 | |
Revenue per Share |
0.00 | 0.00 | 0.08 | 0.04 | |
Operating CF per Share |
(1.91) | (1.93) | (1.19) | (1.22) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | (0.09) |
Columns are period end dates